Showing 13,981 - 14,000 results of 21,342 for search '(( significant decrease decrease ) OR ( significantly ((lower decrease) OR (a decrease)) ))', query time: 0.74s Refine Results
  1. 13981
  2. 13982
  3. 13983
  4. 13984
  5. 13985
  6. 13986
  7. 13987

    Data Sheet 2_Neuron-specific enolase in patients with acute and chronic schizophrenia, diversity of approaches: marker of neuronal death, neurodegeneration or neurodevelopmental th... by Alicja Sierakowska (21248987)

    Published 2025
    “…</p>Results<p>The mean serum concentration of NSE in patients with schizophrenia was statistically significantly lower than in healthy controls. A weak negative correlation between NSE levels and the SANS score and a weak positive correlation between NSE levels and the SAPS score were found, but the results were not statistically significant. …”
  8. 13988

    Data Sheet 1_Neuron-specific enolase in patients with acute and chronic schizophrenia, diversity of approaches: marker of neuronal death, neurodegeneration or neurodevelopmental th... by Alicja Sierakowska (21248987)

    Published 2025
    “…</p>Results<p>The mean serum concentration of NSE in patients with schizophrenia was statistically significantly lower than in healthy controls. A weak negative correlation between NSE levels and the SANS score and a weak positive correlation between NSE levels and the SAPS score were found, but the results were not statistically significant. …”
  9. 13989

    Data Sheet 1_Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systemat... by Yuhua Jiang (10300159)

    Published 2025
    “…Background<p>The objective of this study is to assess the relative efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as alirocumab, evolocumab, and inclisiran, in conjunction with potent statins like atorvastatin and rosuvastatin, in patients presenting with hyperlipidemia or heightened cardiovascular risk attributable to elevated low-density lipoprotein cholesterol (LDL-C).</p>Methods<p>A systematic search was conducted across databases including PubMed, Embase, and the Cochrane Library to explore lipid-lowering therapies in hyperlipidemia from their inception to 7 November 2023. …”
  10. 13990
  11. 13991
  12. 13992
  13. 13993
  14. 13994
  15. 13995
  16. 13996
  17. 13997

    Data Sheet 1_Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036.pdf... by Zilun Wu (18696883)

    Published 2025
    “…Joinpoint regression analysis identified significant shifts in temporal trends, treating 2019 as a key inflection point to observe the pandemic’s impact. …”
  18. 13998

    Table 1_The relationship between dietary sodium intake and all-cause mortality in patients with non-alcoholic fatty liver disease: a cohort study from NHANES 2003–2018.docx by Jiajun Li (1410187)

    Published 2025
    “…Smooth curve fitting and threshold analysis revealed a non-linear association between sodium intake and NAFLD risk, with an inflection point at 2.49 g/d, above which NAFLD risk significantly increased. …”
  19. 13999

    Data Sheet 1_Global, regional and national burden of decubitus ulcers in 204 countries and territories from 1990 to 2021: a systematic analysis based on the global burden of diseas... by Shenyue Zhang (18472266)

    Published 2025
    “…Background<p>Decubitus ulcers, also known as pressure ulcers, pose a significant public health challenge due to their substantial impact on morbidity, mortality, and healthcare expenditures.…”
  20. 14000

    Supplementary Material for: Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio... by figshare admin karger (2628495)

    Published 2025
    “…In VOYAGE I, NLR (p=0.011), PLR (p=0.015) and MLR (p=0.004) decreased significantly following 16 weeks of guselkumab treatment vs. placebo. …”